- Previous Close
19.36 - Open
19.06 - Bid --
- Ask --
- Day's Range
19.06 - 19.06 - 52 Week Range
15.14 - 20.15 - Volume
200 - Avg. Volume
63,719 - Market Cap (intraday)
1.388B - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
17.33 - EPS (TTM)
1.10 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield 0.30 (1.55%)
- Ex-Dividend Date May 21, 2024
- 1y Target Est
22.84
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
www.fagron.com3,828
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: FAGR.BR
View MorePerformance Overview: FAGR.BR
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FAGR.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FAGR.BR
View MoreValuation Measures
Market Cap
1.41B
Enterprise Value
1.68B
Trailing P/E
17.60
Forward P/E
14.66
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
2.81
Enterprise Value/Revenue
1.93
Enterprise Value/EBITDA
10.63
Financial Highlights
Profitability and Income Statement
Profit Margin
9.24%
Return on Assets (ttm)
7.77%
Return on Equity (ttm)
16.65%
Revenue (ttm)
871.96M
Net Income Avi to Common (ttm)
80.55M
Diluted EPS (ttm)
1.10
Balance Sheet and Cash Flow
Total Cash (mrq)
115.92M
Total Debt/Equity (mrq)
76.53%
Levered Free Cash Flow (ttm)
38.45M